Table 3

Incidence and severity of prespecified ocular adverse events in the study eye, all causality
Pegaptanib 0.3 mg
Subjects With Diabetes Without Diabetes
(Nā€‰=ā€‰165 ) (Nā€‰=ā€‰1,421)
Preferred Term1 n (%) Severe n (%) Severe
Cataract, traumatic 0 0 0 1 (0.1) 0
Detachment of retinal pigment epithelium 0 0 0 3 (0.2) 0
Endophthalmitis 1 (0.6) 1 16 (1.1) 14
Eye hemorrhage 0 0 0 6 (0.4) 2
Eye hemorrhage NOS 0 0 0 3 (0.2) 0
Glaucoma 0 0 0 2 (0.1) 0
Glaucoma NOS 0 0 0 2 (0.1) 0
Intraocular pressure increased 13 (7.9) 0 155 (10.9) 6
Ocular hypertension 0 0 0 11 (0.8) 0
Retinal detachment 1 (0.6) 0 9 (0.6) 5
Retinal hemorrhage 8 (4.8) 1 64 (4.5) 6
Retinal pigment epitheliopathy 4 (2.4) 0 10 (0.7) 0
Retinal tear 1 (0.6) 0 0 (0.4) 0
Vitreous hemorrhage 3 (1.8) 0 21 (1.5) 2

1Preferred terms are from MedDRA [Medical Dictionary for Regulatory Activities, version 12.1].

NOS: not otherwise specified.

Dombi et al.

Dombi et al. BMC Ophthalmology 2012 12:37   doi:10.1186/1471-2415-12-37

Open Data